Revolution Medicines Quarterly Income Statements Chart
Quarterly
|
Annual
Revolution Medicines Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| operating expenses: | |||||||||||||||||||||||
| research and development | 224,134,000 | 205,749,000 | 188,096,000 | 151,752,000 | 134,932,000 | 118,021,000 | 148,481,000 | 107,735,000 | 97,981,000 | 68,947,000 | 66,127,000 | 69,455,000 | 61,001,000 | 56,490,000 | 53,681,000 | 46,473,000 | 45,936,000 | 40,858,000 | 37,006,000 | 34,871,000 | 32,918,000 | 27,457,000 | |
| general and administrative | 40,580,000 | 35,011,000 | 28,214,000 | 23,960,000 | 21,711,000 | 22,838,000 | 32,244,000 | 15,513,000 | 14,640,000 | 13,224,000 | 10,910,000 | 10,434,000 | 10,204,000 | 9,037,000 | 8,692,000 | 7,791,000 | 7,297,000 | 6,670,000 | 5,825,000 | 5,341,000 | 5,091,000 | 5,171,000 | |
| total operating expenses | 264,714,000 | 240,760,000 | 216,310,000 | 175,712,000 | 156,643,000 | 140,859,000 | 180,725,000 | 123,248,000 | 112,621,000 | 82,171,000 | 77,037,000 | 79,889,000 | 71,205,000 | 65,527,000 | 62,373,000 | 54,264,000 | 53,233,000 | 47,528,000 | 42,831,000 | 40,212,000 | 38,009,000 | 32,628,000 | |
| income from operations | -264,714,000 | -240,760,000 | -216,310,000 | -175,712,000 | -156,643,000 | -140,859,000 | -179,983,000 | -123,248,000 | -108,797,000 | -75,157,000 | -61,707,000 | -76,533,000 | -62,089,000 | -57,949,000 | -52,913,000 | -53,163,000 | -44,535,000 | -37,397,000 | -34,080,000 | -27,551,000 | -27,984,000 | -21,082,000 | |
| yoy | 68.99% | 70.92% | 20.18% | 42.57% | 43.98% | 87.42% | 191.67% | 61.04% | 75.23% | 29.70% | 16.62% | 43.96% | 39.42% | 54.96% | 55.26% | 92.96% | 59.14% | 77.39% | |||||
| qoq | 9.95% | 11.30% | 23.10% | 12.17% | 11.21% | -21.74% | 46.03% | 13.28% | 44.76% | 21.80% | -19.37% | 23.26% | 7.14% | 9.52% | -0.47% | 19.37% | 19.09% | 9.73% | 23.70% | -1.55% | 32.74% | ||
| operating margin % | -24256.47% | -2845.11% | -1071.53% | -402.52% | -2280.48% | -681.10% | -764.70% | -559.33% | -4828.61% | -512.01% | -369.13% | -389.44% | -217.61% | -279.14% | -182.59% | ||||||||
| other income, net: | |||||||||||||||||||||||
| interest income | 22,404,000 | 24,915,000 | 21,225,000 | 20,411,000 | 21,487,000 | 23,760,000 | 18,977,000 | 10,947,000 | 10,499,000 | 7,059,000 | 5,077,000 | 2,907,000 | 867,000 | 302,000 | 237,000 | 223,000 | 236,000 | 233,000 | 252,000 | 347,000 | 730,000 | 909,000 | |
| interest and other income | -899,000 | -14,250 | -17,000 | -19,000 | -21,000 | ||||||||||||||||||
| change in fair value of warrant liabilities and contingent earn-out shares | -4,578,000 | 2,439,000 | 1,135,750 | -1,269,000 | 1,907,000 | 3,905,000 | |||||||||||||||||
| total other income | 16,927,000 | 27,344,000 | 20,988,000 | 19,424,000 | 23,410,000 | 24,856,000 | 18,789,000 | 10,947,000 | 10,499,000 | 7,059,000 | 5,077,000 | 2,907,000 | 867,000 | 302,000 | 170,000 | 223,000 | 236,000 | 221,000 | 238,000 | 330,000 | 711,000 | 888,000 | |
| income before income taxes | -247,787,000 | -213,416,000 | -195,322,000 | -156,288,000 | -133,233,000 | -116,003,000 | -161,194,000 | -112,301,000 | -98,298,000 | -68,098,000 | -56,630,000 | -73,626,000 | -61,222,000 | -57,647,000 | -52,676,000 | -52,940,000 | -44,299,000 | -37,176,000 | -33,842,000 | -27,221,000 | -27,273,000 | -20,194,000 | |
| net income | -247,787,000 | -213,416,000 | -194,569,000 | -156,288,000 | -133,233,000 | -116,003,000 | -161,537,000 | -108,434,000 | -98,298,000 | -68,098,000 | -56,507,000 | -73,329,000 | -61,222,000 | -57,647,000 | -52,676,000 | -52,940,000 | -44,299,000 | -37,176,000 | -34,204,000 | -27,221,000 | -27,215,000 | -19,519,000 | |
| yoy | 85.98% | 83.97% | 20.45% | 44.13% | 35.54% | 70.35% | 185.87% | 47.87% | 60.56% | 18.13% | 7.27% | 38.51% | 38.20% | 55.07% | 54.01% | 94.48% | 62.77% | 90.46% | |||||
| qoq | 16.11% | 9.69% | 24.49% | 17.30% | 14.85% | -28.19% | 48.97% | 10.31% | 44.35% | 20.51% | -22.94% | 19.78% | 6.20% | 9.44% | -0.50% | 19.51% | 19.16% | 8.69% | 25.65% | 0.02% | 39.43% | ||
| net income margin % | -21770.49% | -2570.55% | -970.89% | -368.60% | -2185.01% | -671.59% | -760.72% | -556.83% | -4808.36% | -509.30% | -366.95% | -390.86% | -215.00% | -271.47% | -169.05% | ||||||||
| net income per share | -1.31 | -1.13 | -1.13 | -0.94 | -0.81 | -0.7 | -1.21 | -0.99 | -0.92 | -0.72 | -0.61 | -0.87 | -0.82 | -0.78 | -0.72 | -0.72 | -0.6 | -0.53 | -0.52 | -0.42 | -0.46 | -0.74 | |
| weighted-average common shares used to compute net income per share, basic and diluted | 188,583,288 | 188,145,904 | 167,737,672 | 166,843,984 | 165,141,936 | 164,729,200 | 113,149,869 | 109,233,084 | 106,884,185 | 94,831,979 | 80,626,525 | 84,694,860 | 74,280,590 | 74,162,363 | 72,806,079 | 73,535,686 | 73,399,714 | 70,420,076 | 54,874,119 | 64,892,868 | 58,752,494 | 29,297,698 | |
| comprehensive loss: | |||||||||||||||||||||||
| other comprehensive loss: | |||||||||||||||||||||||
| unrealized loss on investments | -405 | ||||||||||||||||||||||
| comprehensive loss | -248,192 | -213,030 | -197,060 | -150,613 | -133,898 | -117,745 | -160,122 | -108,054 | -98,993 | -66,874 | |||||||||||||
| other income | -10,000 | -17,000 | 282,000 | 16,000 | -2,809,000 | ||||||||||||||||||
| other comprehensive gain: | |||||||||||||||||||||||
| unrealized gain on investments | 386 | -2,491 | 5,675 | -665 | -1,742 | 1,415 | 380 | -695 | 1,224 | ||||||||||||||
| revenue: | |||||||||||||||||||||||
| collaboration revenue | 742,000 | 3,824,000 | 7,014,000 | 15,330,000 | 3,356,000 | 9,116,000 | 7,578,000 | 9,460,000 | 1,101,000 | 8,698,000 | 10,131,000 | ||||||||||||
| total revenue | 742,000 | 3,824,000 | 7,014,000 | 15,330,000 | 3,356,000 | 9,116,000 | 7,578,000 | 9,460,000 | 1,101,000 | 8,698,000 | 10,131,000 | 8,751,000 | 12,661,000 | 10,025,000 | 11,546,000 | ||||||||
| yoy | -95.16% | -58.05% | -7.44% | 62.05% | 204.81% | 4.81% | -25.20% | 8.10% | -91.30% | -13.24% | -12.26% | ||||||||||||
| qoq | -45.48% | -54.25% | 356.79% | -63.19% | 20.30% | -19.89% | 759.22% | -87.34% | -14.14% | 15.77% | -30.88% | 26.29% | -13.17% | ||||||||||
| benefit from income taxes | 123,000 | 297,000 | -362,000 | 58,000 | 675,000 | ||||||||||||||||||
| benefit from income taxes/ | 966,750 | 3,867,000 | |||||||||||||||||||||
| interest expense | -12,000 | ||||||||||||||||||||||
| redeemable convertible preferred stock dividends - undeclared and cumulative | -2,219,000 | ||||||||||||||||||||||
| net income attributable to common stockholders | -52,676,000 | -52,940,000 | -44,299,000 | -37,176,000 | -34,204,000 | -27,221,000 | -27,215,000 | -21,738,000 | |||||||||||||||
| collaboration revenue, related party | 8,751,000 | 12,661,000 | 10,025,000 | 11,546,000 |
We provide you with 20 years income statements for Revolution Medicines stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Revolution Medicines stock. Explore the full financial landscape of Revolution Medicines stock with our expertly curated income statements.
The information provided in this report about Revolution Medicines stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.